Applications of high-throughput DNA sequencing to benign hematology
Identifieur interne : 005D22 ( Ncbi/Merge ); précédent : 005D21; suivant : 005D23Applications of high-throughput DNA sequencing to benign hematology
Auteurs : Vijay G. Sankaran [États-Unis] ; Patrick G. Gallagher [États-Unis]Source :
- Blood [ 0006-4971 ] ; 2013.
Abstract
The development of novel technologies for high-throughput DNA sequencing is having a major impact on our ability to measure and define normal and pathologic variation in humans. This review discusses advances in DNA sequencing that have been applied to benign hematologic disorders, including those affecting the red blood cell, the neutrophil, and other white blood cell lineages. Relevant examples of how these approaches have been used for disease diagnosis, gene discovery, and studying complex traits are provided. High-throughput DNA sequencing technology holds significant promise for impacting clinical care. This includes development of improved disease detection and diagnosis, better understanding of disease progression and stratification of risk of disease-specific complications, and development of improved therapeutic strategies, particularly patient-specific pharmacogenomics-based therapy, with monitoring of therapy by genomic biomarkers.
Url:
DOI: 10.1182/blood-2013-07-460337
PubMed: 24021670
PubMed Central: 3837507
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 004769
- to stream Pmc, to step Curation: 004768
- to stream Pmc, to step Checkpoint: 002500
Links to Exploration step
PMC:3837507Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Applications of high-throughput DNA sequencing to benign hematology</title>
<author><name sortKey="Sankaran, Vijay G" sort="Sankaran, Vijay G" uniqKey="Sankaran V" first="Vijay G." last="Sankaran">Vijay G. Sankaran</name>
<affiliation wicri:level="2"><nlm:aff id="aff1">Division of Hematology/Oncology, Boston Children’s Hospital, and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Hematology/Oncology, Boston Children’s Hospital, and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><nlm:aff wicri:cut="; and" id="aff2">Broad Institute, Cambridge, MA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Broad Institute, Cambridge</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Gallagher, Patrick G" sort="Gallagher, Patrick G" uniqKey="Gallagher P" first="Patrick G." last="Gallagher">Patrick G. Gallagher</name>
<affiliation wicri:level="2"><nlm:aff id="aff3">Division of Neonatal/Perinatal Medicine, Departments of Pediatrics, Pathology, and Genetics, Yale University School of Medicine, New Haven, CT</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Connecticut</region>
</placeName>
<wicri:cityArea>Division of Neonatal/Perinatal Medicine, Departments of Pediatrics, Pathology, and Genetics, Yale University School of Medicine, New Haven</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">24021670</idno>
<idno type="pmc">3837507</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837507</idno>
<idno type="RBID">PMC:3837507</idno>
<idno type="doi">10.1182/blood-2013-07-460337</idno>
<date when="2013">2013</date>
<idno type="wicri:Area/Pmc/Corpus">004769</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">004769</idno>
<idno type="wicri:Area/Pmc/Curation">004768</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">004768</idno>
<idno type="wicri:Area/Pmc/Checkpoint">002500</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002500</idno>
<idno type="wicri:Area/Ncbi/Merge">005D22</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Applications of high-throughput DNA sequencing to benign hematology</title>
<author><name sortKey="Sankaran, Vijay G" sort="Sankaran, Vijay G" uniqKey="Sankaran V" first="Vijay G." last="Sankaran">Vijay G. Sankaran</name>
<affiliation wicri:level="2"><nlm:aff id="aff1">Division of Hematology/Oncology, Boston Children’s Hospital, and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Hematology/Oncology, Boston Children’s Hospital, and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><nlm:aff wicri:cut="; and" id="aff2">Broad Institute, Cambridge, MA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Broad Institute, Cambridge</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Gallagher, Patrick G" sort="Gallagher, Patrick G" uniqKey="Gallagher P" first="Patrick G." last="Gallagher">Patrick G. Gallagher</name>
<affiliation wicri:level="2"><nlm:aff id="aff3">Division of Neonatal/Perinatal Medicine, Departments of Pediatrics, Pathology, and Genetics, Yale University School of Medicine, New Haven, CT</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Connecticut</region>
</placeName>
<wicri:cityArea>Division of Neonatal/Perinatal Medicine, Departments of Pediatrics, Pathology, and Genetics, Yale University School of Medicine, New Haven</wicri:cityArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Blood</title>
<idno type="ISSN">0006-4971</idno>
<idno type="eISSN">1528-0020</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>The development of novel technologies for high-throughput DNA sequencing is having a major impact on our ability to measure and define normal and pathologic variation in humans. This review discusses advances in DNA sequencing that have been applied to benign hematologic disorders, including those affecting the red blood cell, the neutrophil, and other white blood cell lineages. Relevant examples of how these approaches have been used for disease diagnosis, gene discovery, and studying complex traits are provided. High-throughput DNA sequencing technology holds significant promise for impacting clinical care. This includes development of improved disease detection and diagnosis, better understanding of disease progression and stratification of risk of disease-specific complications, and development of improved therapeutic strategies, particularly patient-specific pharmacogenomics-based therapy, with monitoring of therapy by genomic biomarkers.</p>
</div>
</front>
</TEI>
<pmc article-type="review-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Blood</journal-id>
<journal-id journal-id-type="iso-abbrev">Blood</journal-id>
<journal-id journal-id-type="hwp">bloodjournal</journal-id>
<journal-id journal-id-type="pmc">blood</journal-id>
<journal-id journal-id-type="publisher-id">Blood</journal-id>
<journal-title-group><journal-title>Blood</journal-title>
</journal-title-group>
<issn pub-type="ppub">0006-4971</issn>
<issn pub-type="epub">1528-0020</issn>
<publisher><publisher-name>American Society of Hematology</publisher-name>
<publisher-loc>Washington, DC</publisher-loc>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">24021670</article-id>
<article-id pub-id-type="pmc">3837507</article-id>
<article-id pub-id-type="publisher-id">2013/460337</article-id>
<article-id pub-id-type="doi">10.1182/blood-2013-07-460337</article-id>
<article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>34</subject>
<subject>36</subject>
<subject>53</subject>
</subj-group>
<subj-group subj-group-type="heading"><subject>Review Series</subject>
</subj-group>
<subj-group subj-group-type="leader"><subject>Genome Sequencing and its Impact On Hematology</subject>
</subj-group>
</article-categories>
<title-group><article-title>Applications of high-throughput DNA sequencing to benign hematology</article-title>
</title-group>
<contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Sankaran</surname>
<given-names>Vijay G.</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Gallagher</surname>
<given-names>Patrick G.</given-names>
</name>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<aff id="aff1"><label>1</label>
Division of Hematology/Oncology, Boston Children’s Hospital, and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;</aff>
<aff id="aff2"><label>2</label>
Broad Institute, Cambridge, MA; and</aff>
<aff id="aff3"><label>3</label>
Division of Neonatal/Perinatal Medicine, Departments of Pediatrics, Pathology, and Genetics, Yale University School of Medicine, New Haven, CT</aff>
</contrib-group>
<author-notes><fn fn-type="equal"><p>V.G.S. and P.G.G. contributed equally to this review.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub"><day>21</day>
<month>11</month>
<year>2013</year>
</pub-date>
<pub-date pub-type="epreprint"><day>10</day>
<month>9</month>
<year>2013</year>
</pub-date>
<pub-date pub-type="pmc-release"><day>21</day>
<month>11</month>
<year>2014</year>
</pub-date>
<pmc-comment> PMC Release delay is 12 months and
0 days and was based on the . </pmc-comment>
<volume>122</volume>
<issue>22</issue>
<fpage>3575</fpage>
<lpage>3582</lpage>
<history><date date-type="received"><day>23</day>
<month>7</month>
<year>2013</year>
</date>
<date date-type="accepted"><day>12</day>
<month>8</month>
<year>2013</year>
</date>
</history>
<permissions><copyright-statement>© 2013 by The American Society of Hematology</copyright-statement>
<copyright-year>2013</copyright-year>
</permissions>
<self-uri xlink:title="pdf" xlink:type="simple" xlink:href="3575.pdf"></self-uri>
<related-article related-article-type="companion" id="d35e124" vol="122" page="3268" xlink:href="24021669" ext-link-type="pubmed"></related-article>
<related-article related-article-type="companion" id="d35e125" vol="122" page="3423" xlink:href="24124085" ext-link-type="pubmed"></related-article>
<related-article related-article-type="companion" id="d35e126" vol="122" page="3239" xlink:href="24016460" ext-link-type="pubmed"></related-article>
<abstract><p>The development of novel technologies for high-throughput DNA sequencing is having a major impact on our ability to measure and define normal and pathologic variation in humans. This review discusses advances in DNA sequencing that have been applied to benign hematologic disorders, including those affecting the red blood cell, the neutrophil, and other white blood cell lineages. Relevant examples of how these approaches have been used for disease diagnosis, gene discovery, and studying complex traits are provided. High-throughput DNA sequencing technology holds significant promise for impacting clinical care. This includes development of improved disease detection and diagnosis, better understanding of disease progression and stratification of risk of disease-specific complications, and development of improved therapeutic strategies, particularly patient-specific pharmacogenomics-based therapy, with monitoring of therapy by genomic biomarkers.</p>
</abstract>
<funding-group><award-group><funding-source id="CS100">National Institutes of Health</funding-source>
<award-id rid="CS100">RO1HL065449</award-id>
<award-id rid="CS100">HL007574-30</award-id>
</award-group>
</funding-group>
<counts><page-count count="8"></page-count>
</counts>
</article-meta>
</front>
</pmc>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Connecticut</li>
<li>Massachusetts</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Massachusetts"><name sortKey="Sankaran, Vijay G" sort="Sankaran, Vijay G" uniqKey="Sankaran V" first="Vijay G." last="Sankaran">Vijay G. Sankaran</name>
</region>
<name sortKey="Gallagher, Patrick G" sort="Gallagher, Patrick G" uniqKey="Gallagher P" first="Patrick G." last="Gallagher">Patrick G. Gallagher</name>
<name sortKey="Sankaran, Vijay G" sort="Sankaran, Vijay G" uniqKey="Sankaran V" first="Vijay G." last="Sankaran">Vijay G. Sankaran</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005D22 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 005D22 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= Ncbi |étape= Merge |type= RBID |clé= PMC:3837507 |texte= Applications of high-throughput DNA sequencing to benign hematology }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:24021670" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |